UY26588A1 - Mutantes de ehv gm-negativos - Google Patents

Mutantes de ehv gm-negativos

Info

Publication number
UY26588A1
UY26588A1 UY26588A UY26588A UY26588A1 UY 26588 A1 UY26588 A1 UY 26588A1 UY 26588 A UY26588 A UY 26588A UY 26588 A UY26588 A UY 26588A UY 26588 A1 UY26588 A1 UY 26588A1
Authority
UY
Uruguay
Prior art keywords
ehv
methods
viruses
nucleic acids
infections
Prior art date
Application number
UY26588A
Other languages
English (en)
Inventor
Dr Knut Elbers
Dr Nokolaus Osterrieder
Dr Christian Seyboldt
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of UY26588A1 publication Critical patent/UY26588A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Refiere virus herpes equinos (EHV), donde la proteína GM está esencialmente ausente, o modificada y es no es funcional con respecto a su capacidad inmunomoduladora. Aspectos adicionales se refieren a ácidos nucleicos que codifican dichos virus, a composiciones farmacéuticas comprendiendo estos virus o ácidos nucleicos y sus usos. La invención refiere también a métodos para mejorar la respuesta inmunitaria inducida por vacuna de EHV frente a infecciones de EHV tipo salvaje, a métodos para profilaxia y tratamiento de infecciones de EHV y métodos para distinguir animales infestados con EHV tipo salvaje de animales tratados con EHVs de acuerdo con la invención.
UY26588A 2000-02-17 2001-02-16 Mutantes de ehv gm-negativos UY26588A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00103241A EP1129722A1 (en) 2000-02-17 2000-02-17 gM-negative EHV-mutants

Publications (1)

Publication Number Publication Date
UY26588A1 true UY26588A1 (es) 2001-09-28

Family

ID=8167872

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26588A UY26588A1 (es) 2000-02-17 2001-02-16 Mutantes de ehv gm-negativos

Country Status (24)

Country Link
US (3) US6703231B2 (es)
EP (2) EP1129722A1 (es)
JP (1) JP5177927B2 (es)
KR (1) KR100845192B1 (es)
CN (2) CN101230336A (es)
AR (1) AR027443A1 (es)
AT (1) ATE422363T1 (es)
AU (2) AU4831301A (es)
BR (1) BR0108442A (es)
CA (1) CA2399846C (es)
CO (1) CO5280143A1 (es)
CY (1) CY1109023T1 (es)
CZ (1) CZ303657B6 (es)
DE (1) DE60137621D1 (es)
DK (1) DK1259258T3 (es)
ES (1) ES2322236T3 (es)
HK (1) HK1052462A1 (es)
HU (1) HU228217B1 (es)
MX (1) MXPA02008009A (es)
NZ (1) NZ521365A (es)
PL (1) PL210441B1 (es)
PT (1) PT1259258E (es)
UY (1) UY26588A1 (es)
WO (1) WO2001060403A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129722A1 (en) * 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
DE10233064A1 (de) * 2002-07-19 2004-02-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-Mutanten ohne heterologe Elemente
AR040601A1 (es) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
EP1394258A1 (en) * 2002-08-30 2004-03-03 Geneart GmbH Non-human herpesviruses as vectors
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731188A (en) * 1986-11-20 1998-03-24 Syntro Corporation Recombinant equine herpesviruses
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US5674735A (en) * 1990-07-06 1997-10-07 University Court Of The University Of Glasgow DNA encoding the EHV-4 gH or gC glycoprotein
DE4110962A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
ATE259417T1 (de) * 1992-06-01 2004-02-15 Univ Melbourne Immunologisches verfahren für die detektion von pferde-herpesvirus typ 1 und 4 glycoprotein g antikörper
US5853715A (en) * 1996-08-16 1998-12-29 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
GB9625968D0 (en) 1996-12-13 1997-01-29 Univ Glasgow Vaccine
GB9626029D0 (en) * 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
AU758604B2 (en) 1998-07-31 2003-03-27 Intervet International B.V. Attenuated equine herpesvirus
WO2001017553A1 (en) 1999-09-10 2001-03-15 Akzo Nobel N.V. Equine herpes virus temperature sensitive mutant and live vaccine thereof
EP1129722A1 (en) * 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
WO2002009750A2 (en) 2000-07-27 2002-02-07 Research Corporation Technologies, Inc. Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
DE10233064A1 (de) 2002-07-19 2004-02-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-Mutanten ohne heterologe Elemente
AR040601A1 (es) * 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos

Also Published As

Publication number Publication date
HUP0204446A2 (en) 2003-05-28
CO5280143A1 (es) 2003-05-30
CA2399846A1 (en) 2001-08-23
US20030198650A1 (en) 2003-10-23
HK1052462A1 (zh) 2003-09-19
AU2001248313B2 (en) 2006-03-02
BR0108442A (pt) 2003-03-25
CZ303657B6 (cs) 2013-02-06
PL210441B1 (pl) 2012-01-31
CA2399846C (en) 2011-06-14
AU4831301A (en) 2001-08-27
NZ521365A (en) 2004-07-30
PT1259258E (pt) 2009-03-18
CN100378216C (zh) 2008-04-02
HUP0204446A3 (en) 2010-01-28
CN101230336A (zh) 2008-07-30
US20040063095A1 (en) 2004-04-01
CZ20022809A3 (cs) 2003-01-15
EP1129722A1 (en) 2001-09-05
DK1259258T3 (da) 2009-06-02
EP1259258A1 (en) 2002-11-27
DE60137621D1 (de) 2009-03-26
ATE422363T1 (de) 2009-02-15
PL357019A1 (en) 2004-07-12
KR100845192B1 (ko) 2008-07-10
JP2003522542A (ja) 2003-07-29
AR027443A1 (es) 2003-03-26
HU228217B1 (en) 2013-02-28
CN1400907A (zh) 2003-03-05
WO2001060403A1 (en) 2001-08-23
CY1109023T1 (el) 2014-07-02
MXPA02008009A (es) 2003-01-28
ES2322236T3 (es) 2009-06-18
KR20030032914A (ko) 2003-04-26
US20080160046A1 (en) 2008-07-03
US8017317B2 (en) 2011-09-13
JP5177927B2 (ja) 2013-04-10
EP1259258B1 (en) 2009-02-11
US7309598B2 (en) 2007-12-18
US6703231B2 (en) 2004-03-09

Similar Documents

Publication Publication Date Title
DK1129190T3 (da) Human TSLP DNA og polypeptider
DE69519521D1 (de) Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
BR0107703A (pt) Flavivìrus recombinantes e processos para uso dos mesmos
NO944245L (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
MXPA05005202A (es) Vacuna.
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
CY1109023T1 (el) Gm-αρνητικα μεταλλαγματα ehv
BR9907883A (pt) Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
ATE550426T1 (de) Polypeptide zur auslösung einer immunreaktion gegen krebs
ES2561483T3 (es) Antígenos mutantes de GAS57 y anticuerpos de GAS57
DK0507179T3 (da) Equine herpesvira (EHV), der indeholder fremmed
YU12991A (sh) Rekombinantne vakcine protiv kokcidioze-5-7 eimeria površinski antigen
ATE543513T1 (de) Anti-coronavirus impfstoff
CY1109206T1 (el) gM- ΑΡΝΗΤΙΚΟΙ EHV-ΜΕΤΑΛΛΑΚΤΕΣ ΧΩΡΙΣ ΕΤΕΡΟΛΟΓΑ ΣΤΟΙΧΕΙΑ
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
AR040601A1 (es) Mutantes ehv negativos de gm sin elementos heterologos
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
BR9915970A (pt) Vìrus recombinante expressando dna exógenocodificando cd80 felino, ctla-4 felino ou cd86 felinoe usos do mesmo
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
ATE344802T1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20121105